keptrohy glp-1 activation receptor assay: drug discovery in the metabolic field GLP-1 Activation for Women &

reports on their association are conflicting

Obesity rates among adults have more than doubled since 1990, from 7% to 16% in 2022, according to the World Health Organization (WHO)

Why this matters: Daily oral semaglutide offers an alternative to weekly injections Lower cash prices compared to injectables: $149$299/month Available at 70,000+ pharmacies (CVS, Costco) and telehealth platforms like Ro, LifeMD, Weight Watchers, GoodRx, and NovoCare Approved not only for weight loss, but also for reducing cardiovascular risk in adults with obesity Clinical impact: Phase 3 trials showed up to 16.6% average weight loss at 64 weeks Same active ingredient as injectable Wegovy, targeting appetite via GLP-1 pathways Industry perspective: With the global GLP-1 market projected to approach $100B by the 2030s, oral therapies may capture nearly 24% of the market, reshaping access, adherence, and affordability

S.StoberF.et al (2016)

31 demonstrated similar safety in 4-P MACE in a meta-analysis which included 4,487 participants treated with tirzepatide and 2,328 participants in control arm from seven trials which lasted more than 26 weeks duration